HUP0102260A2 - ACE inhibitorokat tartalmazó kompozíciók stabilizálása magnézium-oxid alkalmazásával - Google Patents

ACE inhibitorokat tartalmazó kompozíciók stabilizálása magnézium-oxid alkalmazásával

Info

Publication number
HUP0102260A2
HUP0102260A2 HU0102260A HUP0102260A HUP0102260A2 HU P0102260 A2 HUP0102260 A2 HU P0102260A2 HU 0102260 A HU0102260 A HU 0102260A HU P0102260 A HUP0102260 A HU P0102260A HU P0102260 A2 HUP0102260 A2 HU P0102260A2
Authority
HU
Hungary
Prior art keywords
magnesium oxide
compositions containing
stabilizer
hydrolysis
suitable amount
Prior art date
Application number
HU0102260A
Other languages
English (en)
Inventor
Jane Ellen Daniel
Michael Ray Harris
Gerard Clifford Hokanson
Jay Weiss
Original Assignee
Warner-Lambert Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0102260(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Co. filed Critical Warner-Lambert Co.
Publication of HUP0102260A2 publication Critical patent/HUP0102260A2/hu
Publication of HUP0102260A3 publication Critical patent/HUP0102260A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Abstract

A találmány ACE-inhibitort tartalmazó, magnézium-oxid jelenléte általstabilizált kompozíciókra vonatkozik, amelyek a következő összetevőkettartalmazzák: (a) egy ciklizációra, hidrolízisre és/vagyszínváltozásra hajlamos ACE-inhibitor alkalmas mennyiségéből állóhatóanyag-komponens; (b) alkalmas mennyiségben egy, a ciklizáció és aszínváltozás visszatartására szolgáló stabilizátor, amely stabilizátorlényegében magnézium-oxidból áll, és (c) alkalmas mennyiségben egy, ahidrolízis megakadályozására szolgáló hidrolízisminimalizáló szer.Előnyösen a quinapril ACE-inhibitort védik meg a degradáció bizonyosformáitól, amikor a hatóanyagból egy stabilizálószerként alapvetőenmagnézium-oxidot tartalmazó gyógyszerkészítményt állítanak elő. Amagnézium-oxid jelenléte előnyös eljárási körülményeket biztosít azACE-inhibitort tartalmazó kompozíciók előállításához, különösen nedvesgranulálással történő előállításához. Ó
HU0102260A 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide HUP0102260A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05
PCT/US1999/010189 WO1999062560A1 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Publications (2)

Publication Number Publication Date
HUP0102260A2 true HUP0102260A2 (hu) 2002-03-28
HUP0102260A3 HUP0102260A3 (en) 2002-12-28

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102260A HUP0102260A3 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Country Status (32)

Country Link
US (3) US6417196B1 (hu)
EP (1) EP1083931B1 (hu)
JP (1) JP3727848B2 (hu)
KR (1) KR20010052557A (hu)
CN (1) CN1144598C (hu)
AR (1) AR019150A1 (hu)
AT (1) ATE295184T1 (hu)
AU (1) AU755616B2 (hu)
BR (1) BR9910947A (hu)
CA (1) CA2330581A1 (hu)
CO (1) CO5011043A1 (hu)
DE (1) DE69925269T2 (hu)
ES (1) ES2242398T3 (hu)
GT (1) GT199900079A (hu)
HK (1) HK1038879B (hu)
HN (1) HN1999000088A (hu)
HU (1) HUP0102260A3 (hu)
ID (1) ID27398A (hu)
IL (1) IL139590A0 (hu)
IS (1) IS2270B (hu)
MY (1) MY119667A (hu)
NO (1) NO20006148D0 (hu)
NZ (1) NZ508544A (hu)
PA (1) PA8475001A1 (hu)
PE (1) PE20000543A1 (hu)
PL (1) PL344586A1 (hu)
SV (1) SV1999000072A (hu)
TR (1) TR200003600T2 (hu)
TW (1) TW565455B (hu)
UY (1) UY25546A1 (hu)
WO (1) WO1999062560A1 (hu)
ZA (1) ZA200006537B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3727848B2 (ja) * 1998-06-05 2005-12-21 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 酸化マグネシウムを使用する、ａｃｅ阻害剤を含有する組成物の安定化
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
DK1300160T3 (da) * 2000-05-24 2014-03-24 Otsuka Pharma Co Ltd Fremgangsmåde til stabilisering af en sammensætning
ATE357933T1 (de) * 2002-01-15 2007-04-15 Actavis Group Hf Formulierungen von quinapril und verwandte ace- hemmer
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
WO2004073729A1 (ja) * 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
MXPA06000226A (es) * 2003-06-26 2006-03-21 Teva Pharma Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3..0]-octano-3-carboxilico.
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) * 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
WO2007120930A2 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
WO2008000040A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ace inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8337817B2 (en) 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) * 1967-05-16 Method of preparing magnesia
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
JP3727848B2 (ja) * 1998-06-05 2005-12-21 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 酸化マグネシウムを使用する、ａｃｅ阻害剤を含有する組成物の安定化
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
DE69925269D1 (de) 2005-06-16
ATE295184T1 (de) 2005-05-15
GT199900079A (es) 2000-11-25
US6417196B1 (en) 2002-07-09
ZA200006537B (en) 2001-11-12
JP3727848B2 (ja) 2005-12-21
AR019150A1 (es) 2001-12-26
IS2270B (is) 2007-07-15
DE69925269T2 (de) 2006-02-23
PE20000543A1 (es) 2000-08-10
CO5011043A1 (es) 2001-02-28
ES2242398T3 (es) 2005-11-01
SV1999000072A (es) 2000-05-04
WO1999062560A1 (en) 1999-12-09
HK1038879B (zh) 2004-10-08
CN1144598C (zh) 2004-04-07
US20020161020A1 (en) 2002-10-31
NZ508544A (en) 2002-10-25
HK1038879A1 (en) 2002-04-04
PA8475001A1 (es) 2000-09-29
EP1083931A1 (en) 2001-03-21
HN1999000088A (es) 2000-02-10
JP2002516881A (ja) 2002-06-11
AU3979399A (en) 1999-12-20
PL344586A1 (en) 2001-11-05
HUP0102260A3 (en) 2002-12-28
TR200003600T2 (tr) 2001-04-20
KR20010052557A (ko) 2001-06-25
CN1304322A (zh) 2001-07-18
MY119667A (en) 2005-06-30
AU755616B2 (en) 2002-12-19
NO20006148L (no) 2000-12-04
ID27398A (id) 2001-04-05
CA2330581A1 (en) 1999-12-09
EP1083931B1 (en) 2005-05-11
TW565455B (en) 2003-12-11
NO20006148D0 (no) 2000-12-04
US20060106057A1 (en) 2006-05-18
BR9910947A (pt) 2001-03-06
US7015232B2 (en) 2006-03-21
IS5712A (is) 2000-11-10
IL139590A0 (en) 2002-02-10
UY25546A1 (es) 1999-09-27

Similar Documents

Publication Publication Date Title
HUP0102260A2 (hu) ACE inhibitorokat tartalmazó kompozíciók stabilizálása magnézium-oxid alkalmazásával
NO20052690D0 (no) Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke.
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
MY120064A (en) Indole derivatives as inhibitors or factor xa
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ECSP045378A (es) Derivados novedosos de diazabiciclononeno
CA2367017A1 (en) Inhibitors of impdh enzyme
HUP0102550A2 (hu) IgE választ befolyásoló tulajdonságú vegyületek
WO2005044195A3 (en) Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2004050022A3 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2001087882A3 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
TW200514772A (en) Novel tetrahydropyridine derivatives
BR0108694A (pt) Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos
TW200517389A (en) Biaryloxymethylarenecarboxylic acids
WO2001009169A3 (en) Cysteine protease inhibitors
AU7092296A (en) Pharmaceutical compositions containing hydroximic acid derivatives
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
MXPA05011497A (es) Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
WO2003075842A3 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
HUP0101224A2 (hu) Neuraminidáz inhibitor hatású pirrolidinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények
WO2002072581A3 (en) Pyrazolopyriadine derivatives
DE69805860D1 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
WO2003104189A3 (en) COMPOUNDS
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees